The state of Alabama currently has 5 active clinical trials seeking participants for Rheumatoid Arthritis research studies. These trials are conducted in various cities, including Birmingham, Mobile, Huntsville and Anniston.
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: East Alabama Arthritis Center PC, Auburn, Alabama +2 locations
Conditions: Rheumatoid Arthritis
Splenic Stimulation for RA
Recruiting
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active r... Read More
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
02/12/2024
Locations: Pinnacle Research Group, LLC, Anniston, Alabama
Conditions: Rheumatoid Arthritis
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Anniston Medical Clinic, Anniston, Alabama
Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
COVID-19 VaccinE Response in Rheumatology Patients
Recruiting
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. The investigators propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prio... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/06/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +2 locations
Conditions: Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis